HPC Offered for PRESERVE Expansion
Allogeneic bone marrow transplantation is a highly effective and time-tested treatment for an array of hematologic diseases. However, far too many of the patients that could benefit from a bone marrow transplant are unable to receive one due to inadequate access to bone marrow donors.
At Ossium, we envision a future in which every blood cancer patient has access to a bone marrow donor. In pursuit of this vision, we’ve established a first-of-its-kind bank of cryopreserved organ donor-derived bone marrow to dramatically expand patient access to bone marrow transplantation.
We recently launched the PRESERVE I clinical study of our bone marrow product in acute leukemia patients who require an allogeneic bone marrow transplant. Through this multi-center clinical study, acute leukemia patients who don’t have a suitable living donor have a new opportunity to receive a bone marrow transplant.
We recognize that there are many patients in need of a bone marrow donor that cannot participate in the PRESERVE I study due to its eligibility criteria or for logistical reasons. For these patients, it may feel like there is no hope. To serve these patients and further our company mission, we’ve launched the Ossium HOPE Program. Through this program, we’re expanding access to our bone marrow product to patients outside of the PRESERVE I study.
Patients aged 18-70 may be eligible to receive bone marrow for transplantation through the Ossium HOPE Program* if:
- They were diagnosed with a blood cancer
- Their treating physician determined they are eligible for allogeneic bone marrow transplant
- Their treating physician determined that the potential benefit outweighs the potential risks
Patients, their family or friends, and healthcare providers may request information about participating in the Ossium HOPE Program by submitting information in the form below.
* Ossium reserves the right to discontinue or change the terms of the Ossium HOPE Program (including the key patient criteria) at any time in its sole discretion. Ossium reserves the right to make the final determination regarding whether a patient meets the key patient criteria for the Ossium HOPE Program in its sole discretion.
Frequently Asked Questions
The HOPE Program provides an opportunity for blood cancer patients to receive bone marrow from our bank when they can’t participate in the PRESERVE I clinical study.
Adults with blood cancer that are unable to participate in the PRESERVE I clinical study may be eligible to participate in the HOPE Program. The patient’s doctor must determine that they are eligible for an allogeneic bone marrow transplant and that the potential benefits outweigh the potential risks. The determination on program eligibility is made by Ossium’s clinical staff based on information provided by the patient and their doctor.*
This program provides patients with a unique mechanism to access bone marrow from our bank even if they cannot participate in the PRESERVE I clinical study. Bone marrow from our bank could provide benefits to the patient, including increased donor choice, decreased time to transplant, and optimal cell dose.
Bone marrow in our bank is derived from the vertebrae of consented and rigorously screened organ donors. We obtain vertebral bodies from organ donors through partnerships with the organizations responsible for solid organ procurement and distribution in the US. The vertebral bodies are processed in our production facility under a highly controlled process and stored in freezers at cryogenic temperatures until ready for use.
After you express interest in participating in this program by completing the form above, we’ll request additional information from you and your doctor to determine whether there’s a matching donor in our bank. Once your doctor provides your HLA type, we can search for a matching donor. We will keep you informed on every step of the way.
Bone marrow donors in Ossium’s bank undergo rigorous screening and testing for relevant communicable disease agents by both the Organ Procurement Organizations and a dedicated donor management team at Ossium Health. Ossium donors have been confirmed by our Medical Director to be free from risk factors for, and clinical evidence of, infection due to relevant communicable disease agents and diseases. Bone marrow in our bank is processed, tested, and stored in a manner to ensure the highest level of product quality.
The doctor you’re already seeing will perform the transplant. Any bone marrow transplant physician in the US can perform a transplant with bone marrow from our bank.
We will provide bone marrow to HOPE Program patients at no cost.
The bone marrow transplant procedure itself is not covered by Ossium. This is considered a medical procedure that is treated the same as a transplant from a living donor. We encourage participants to seek information from the transplant center and their health insurance provider about insurance coverage for this procedure.
No. Ossium’s bone marrow bank is sourced from deceased organ donors and we do not bank bone marrow from living donors. We encourage anyone interested in becoming a living bone marrow donor to join the NMDP living donor bone marrow registry.
No. We encourage anyone interested in becoming a living bone marrow donor to join NMDP’s registry.
You can reach Ossium’s patient support team at [email protected] or (628) 677-4863.